K

Kardigan, Inc.

KARDPro tracking

Kardigan, Inc. · Nasdaq · Research source · 424B4 · 2026-06-18 · Latest filing · 10-Q · 2026-11-12 SEC ↗

Report source
Research source · 424B4 · 2026-06-18
SummaryBASIC RESEARCHReport source · 424B4

IPO research

The final prospectus dated June 17, 2026 priced 25,000,000 primary shares at $16, with a 30-day option for 3,750,000 more. It states Nasdaq approval under KARD and expected delivery around June 22, 2026; those historical statements do not independently confirm current trading or settlement.

Full source-backed summary

Kardigan is a well-funded but pre-revenue cardiovascular biotech advancing three mid-to-late-stage candidates in parallel. The $400 million IPO extends its stated runway into 2028 and funds defined clinical milestones, but the investment remains highly dependent on unapproved assets, costly trials, licensed rights and future financing. The $1.43 billion offer-price equity value and 55.4% tangible-book dilution price in substantial execution expectations.

The final prospectus dated June 17, 2026 priced 25,000,000 primary shares at $16, with a 30-day option for 3,750,000 more. It states Nasdaq approval under KARD and expected delivery around June 22, 2026; those historical statements do not independently confirm current trading or settlement.

Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointNext research checkpoint: verify completed Nasdaq trading and closing, option exercise, 2026 trial enrollment updates, and the stated first-half 2027 Danicamtiv/Tonlamarsen and 2027 Ataciguat readouts.424B4 · 2026-06-18
Business and development direction

Kardigan, Inc.

Current business
Future development
DECISION DRIVERS

Key risks

Risk 1

No product is approved and no revenue has been generated; commercial revenue is not expected for at least several years, if ever.

Risk 2

Quarterly net loss more than tripled year over year to $56.1 million as three programs advanced in parallel.

Risk 3

The Prolaio approach to trial design is novel and may fail to deliver anticipated efficiency or regulatory acceptance.

Next checkNext research checkpoint: verify completed Nasdaq trading and closing, option exercise, 2026 trial enrollment updates, and the stated first-half 2027 Danicamtiv/Tonlamarsen and 2027 Ataciguat readouts.
Latest filing2026-11-12
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualitySome sourced inputs are available; a compatible set is needed for this view. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
CONFIRMED
#InstitutionUnderwriting allocationRatio · calculatedShares
1J.P. Morgan Securities LLC35.75%8,937,500 shares
2Jefferies LLC25.75%6,437,500 shares
3Leerink Partners LLC20.75%5,187,500 shares
4TD Securities (USA) LLC17.75%4,437,500 shares

Ratio = institution commitment ÷ complete source-table total (25,000,000 shares) × 100.

Source and calculation

Allocation ratios are calculated from each reported commitment and the complete total in the same source table; they are not ownership or fee percentages.

Underwriting purchase commitments as disclosed; shares; source class retained in the column header; source column: Number ofshares

Number ofshares

SEC table 696 row 9; source 1990301:1993813; SHA256 e2df8f5c5186736ff6f90e3ddeaeeaa2efce1a19c278f3c0e809336646178338

J.P. Morgan Securities LLC: 8937500 / 25000000 × 100

Jefferies LLC: 6437500 / 25000000 × 100

Leerink Partners LLC: 5187500 / 25000000 × 100

TD Securities (USA) LLC: 4437500 / 25000000 × 100

Source · 424B4 ↗

Underwriting terms

Underwriting terms
MeasureReported valueUnit
Underwriting discount per share$1.12$ / share
Total underwriting discount$28,000,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Underwriting discount per share

Base prospectus offering; cover per-share and total columns

SEC table 1 row 7; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Total underwriting discount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 7; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗

IPO CAPITAL QUALITY

Offering price $ / share$16
Gross offering amount $$400,000,000
Issuer proceeds before expenses $$372,000,000
Underwriting discount per share $ / share$1.12
Basis and evidence

424B4 · 2026-06-18

The final prospectus dated June 17, 2026 priced 25,000,000 primary shares at $16, with a 30-day option for 3,750,000 more. It states Nasdaq approval under KARD and expected delivery around June 22, 2026; those historical statements do not independently confirm current trading or settlement.

Offering structure

Offering terms
MeasureReported valueUnit
Offering price$16$ / share
Gross offering amount$400,000,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Gross offering amount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 5; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗

Proceeds and intended uses

Proceeds and intended uses
MeasureReported valueUnit
Issuer proceeds before expenses$372,000,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Issuer proceeds before expenses

Base prospectus offering; cover per-share and total columns

SEC table 1 row 9; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗

Dilution and valuation

IPO price$16Final
Basic post-offer≈ 89.3391M
Equity value≈ $1.4294B
Dilution and valuation
CalculationSharesValueReference
Base post-offer valuation≈ 89.3391M≈ $1.4294B
Derived calculationFinalshares · $Basis and evidence 6 ↗
Post-offer shares — base/no option89,339,121—
Reported sourcePost-offer · BasesharesBasis and evidence 4 ↗
Post-offer shares — full option93,089,121—
Reported sourcePost-offer · Full optionsharesBasis and evidence 4 ↗
Offering price—$16
Reported sourceFinal$/shareBasis and evidence 3 ↗
Gross offering amount—$400,000,000
Reported source$Basis and evidence 3 ↗
Basis and evidence ↗
Basis and evidence 1

Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 49 row 1 columns 2; share summary; label column 1; source 78290:79366; SHA256 ae89f2f0b120737eb12bed96a1b277c3c5a7408b04adf2accaa43cee989dc20c ↗

Basis and evidence 2

Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 49 row 1 columns 2; share summary; label column 1; source 78290:79366; SHA256 ae89f2f0b120737eb12bed96a1b277c3c5a7408b04adf2accaa43cee989dc20c ↗

Basis and evidence 3

Base prospectus offering; cover per-share and total columns

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

SEC table 1 row 5; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗

Basis and evidence 4

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Offering price: $16

Exact input · Post-offer shares — base/no option: 89,339,121

Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — full option: 93,089,121

SEC table 1 row 5; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗

SEC table 49 row 1 columns 2; share summary; label column 1; source 78290:79366; SHA256 ae89f2f0b120737eb12bed96a1b277c3c5a7408b04adf2accaa43cee989dc20c ↗

SEC valuation primary issuer cover; source 1004:1227; SHA256 df837b04c90b64012124b07c1fb7c4d97b726235b7d36528d0b958af3c33a370 ↗

SEC valuation summary conditions; source 74671:77088; SHA256 3a2c6c01ff3a201d1ca77ac993a5624ecfe78c46c87c44cbf97b4009416de00c ↗

SEC valuation summary conditions; source 82202:101546; SHA256 6ad534adcfd9554ba32833e1819a61ff77e30bdb64eb0cd36b6c9069fdc4b747 ↗

Basis and evidence 5

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

SEC table 1 row 5; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗

SEC table 49 row 1 columns 2; share summary; label column 1; source 78290:79366; SHA256 ae89f2f0b120737eb12bed96a1b277c3c5a7408b04adf2accaa43cee989dc20c ↗

SEC valuation primary issuer cover; source 1004:1227; SHA256 df837b04c90b64012124b07c1fb7c4d97b726235b7d36528d0b958af3c33a370 ↗

SEC valuation summary conditions; source 74671:77088; SHA256 3a2c6c01ff3a201d1ca77ac993a5624ecfe78c46c87c44cbf97b4009416de00c ↗

SEC valuation summary conditions; source 82202:101546; SHA256 6ad534adcfd9554ba32833e1819a61ff77e30bdb64eb0cd36b6c9069fdc4b747 ↗

Basis and evidence 6

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — base/no option: 89,339,121

Exact input · Offering price: $16

SEC table 1 row 5; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗

SEC table 49 row 1 columns 2; share summary; label column 1; source 78290:79366; SHA256 ae89f2f0b120737eb12bed96a1b277c3c5a7408b04adf2accaa43cee989dc20c ↗

SEC valuation primary issuer cover; source 1004:1227; SHA256 df837b04c90b64012124b07c1fb7c4d97b726235b7d36528d0b958af3c33a370 ↗

SEC valuation summary conditions; source 74671:77088; SHA256 3a2c6c01ff3a201d1ca77ac993a5624ecfe78c46c87c44cbf97b4009416de00c ↗

SEC valuation summary conditions; source 82202:101546; SHA256 6ad534adcfd9554ba32833e1819a61ff77e30bdb64eb0cd36b6c9069fdc4b747 ↗

Share-count comparison

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Offering completion · $16 × ≈ 89.3391M shares · Final

Implied equity value≈ $1.4294BPrice × post-offer shares
Post-offer shares≈ 89.3391MShare count, not tradable float
Existing-holder ownership reduction0.0%Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.

Base post-offer shares

Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.

Equity value

Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.

Share-count change

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Alternative scenarios

Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.

Sensitivity

The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

$16 × 89,339,121 = $1,429,425,936 [summary-table-49-base-1-price, summary-table-49-base-1-post]

Exact calculation · Derived whole-issuer equity value: $1,429,425,936

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesSome sourced inputs are available; a compatible set is needed for this view. Open filing ↗
As of
2026-06-18
!Ownership remains concentrated among ARCH, HRTG, Perceptive and management, without a single disclosed majority controller.View source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · Kardigan, Inc.
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliatesOwnership as disclosed—approximately 86.0%Beneficial—
Source statement; approximately ; source predicate: beneficially owned; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) ; source scope: of our voting stock and, upon the completion of this offering, that same group will hold approximately; not an additive ownership partitionDisclosedEvidence
our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliatesOwnership as disclosed—approximately 63.5%Beneficial—
Source statement; approximately ; source predicate: will hold; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) ; source scope: of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of ou; not an additive ownership partitionDisclosedEvidence
Entities affiliated with ARCHBeneficial shares14,668,075——
Number of sharesbeneficially ownedDisclosedEvidence
Entities affiliated with HRTG PartnersBeneficial shares14,688,074——
Number of sharesbeneficially ownedDisclosedEvidence
Entities affiliated with PerceptiveBeneficial shares8,200,661——
Number of sharesbeneficially ownedDisclosedEvidence
Entities affiliated with FidelityBeneficial shares4,473,086——
Number of sharesbeneficially ownedDisclosedEvidence
Tassos Gianakakos, Chief Executive Officer, Director, and ChairBeneficial shares9,806,633——
Number of sharesbeneficially ownedDisclosedEvidence
Jay Edelberg, M.D., Ph.D., Chief Medical OfficerBeneficial shares4,599,237——
Number of sharesbeneficially ownedDisclosedEvidence
Brianne Puglisi, Chief Financial OfficerBeneficial shares184,718——
Number of sharesbeneficially ownedDisclosedEvidence
Andy Pasternak, Chief Strategy OfficerBeneficial shares31,339——
Number of sharesbeneficially ownedDisclosedEvidence
Paul BernsBeneficial shares53,483——
Number of sharesbeneficially ownedDisclosedEvidence
David Meeker, M.D.Beneficial shares37,358——
Number of sharesbeneficially ownedDisclosedEvidence
Douglas GiordanoBeneficial shares53,483——
Number of sharesbeneficially ownedDisclosedEvidence
Kim PopovitsBeneficial shares37,358——
Number of sharesbeneficially ownedDisclosedEvidence
Entities affiliated with ARCHBeneficial ownership—22.4%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Entities affiliated with ARCHBeneficial ownership—16.5%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Entities affiliated with HRTG PartnersBeneficial ownership—22.4%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Entities affiliated with HRTG PartnersBeneficial ownership—16.6%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Entities affiliated with PerceptiveBeneficial ownership—12.7%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Entities affiliated with PerceptiveBeneficial ownership—9.3%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Entities affiliated with FidelityBeneficial ownership—6.9%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Entities affiliated with FidelityBeneficial ownership—5.1%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Tassos Gianakakos, Chief Executive Officer, Director, and ChairBeneficial ownership—15.2%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Tassos Gianakakos, Chief Executive Officer, Director, and ChairBeneficial ownership—11.2%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
Jay Edelberg, M.D., Ph.D., Chief Medical OfficerBeneficial ownership—7.1%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
Jay Edelberg, M.D., Ph.D., Chief Medical OfficerBeneficial ownership—5.2%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
All executive officers and directors as a group (10 persons)Beneficial shares14,803,609——
Number of sharesbeneficially ownedDisclosedEvidence
All executive officers and directors as a group (10 persons)Beneficial ownership—22.6%Beneficial—
Percentage of sharesbeneficially owned; BeforeofferingDisclosedEvidence
All executive officers and directors as a group (10 persons)Beneficial ownership—16.6%Beneficial—
Percentage of sharesbeneficially owned; AfterofferingDisclosedEvidence
voting common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; voting common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicableDisclosedEvidence
Source and calculation ↗
our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates · our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates — Ownership as disclosed · approximately 86.0%

Source statement; approximately ; source predicate: beneficially owned; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) ; source scope: of our voting stock and, upon the completion of this offering, that same group will hold approximately; not an additive ownership partition

Based on the beneficial ownership of our common stock as of June 5, 2026, prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 86.0% of our voting stock and, upon the completion of this offering, that same group will hold approximately 63.5% of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) no purchases of shares by this group in this offering), in each case assuming the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger,

0001193125-26-276096 · SEC ownership paragraph; source 734503:735709; SHA256 3dad0d477fd20a0d794719257d0eb89849a19cea0d74393844be07419dd00169 ↗

our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates · our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates — Ownership as disclosed · approximately 63.5%

Source statement; approximately ; source predicate: will hold; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) ; source scope: of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of ou; not an additive ownership partition

Based on the beneficial ownership of our common stock as of June 5, 2026, prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 86.0% of our voting stock and, upon the completion of this offering, that same group will hold approximately 63.5% of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) no purchases of shares by this group in this offering), in each case assuming the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger,

0001193125-26-276096 · SEC ownership paragraph; source 734503:735709; SHA256 3dad0d477fd20a0d794719257d0eb89849a19cea0d74393844be07419dd00169 ↗

Entities affiliated with ARCH · Entities affiliated with ARCH — Beneficial shares · 14,668,075

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Entities affiliated with ARCH (1)

0001193125-26-276096 · SEC table 652 row 7 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Entities affiliated with HRTG Partners · Entities affiliated with HRTG Partners — Beneficial shares · 14,688,074

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Entities affiliated with HRTG Partners (2)

0001193125-26-276096 · SEC table 652 row 8 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Entities affiliated with Perceptive · Entities affiliated with Perceptive — Beneficial shares · 8,200,661

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Entities affiliated with Perceptive (3)

0001193125-26-276096 · SEC table 652 row 9 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Entities affiliated with Fidelity · Entities affiliated with Fidelity — Beneficial shares · 4,473,086

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Entities affiliated with Fidelity (4)

0001193125-26-276096 · SEC table 652 row 10 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Tassos Gianakakos, Chief Executive Officer, Director, and Chair · Tassos Gianakakos, Chief Executive Officer, Director, and Chair — Beneficial shares · 9,806,633

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Tassos Gianakakos, Chief Executive Officer, Director, and Chair (5)

0001193125-26-276096 · SEC table 652 row 13 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Jay Edelberg, M.D., Ph.D., Chief Medical Officer · Jay Edelberg, M.D., Ph.D., Chief Medical Officer — Beneficial shares · 4,599,237

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Jay Edelberg, M.D., Ph.D., Chief Medical Officer (6)

0001193125-26-276096 · SEC table 652 row 14 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Brianne Puglisi, Chief Financial Officer · Brianne Puglisi, Chief Financial Officer — Beneficial shares · 184,718

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Brianne Puglisi, Chief Financial Officer (7)

0001193125-26-276096 · SEC table 652 row 15 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Andy Pasternak, Chief Strategy Officer · Andy Pasternak, Chief Strategy Officer — Beneficial shares · 31,339

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Andy Pasternak, Chief Strategy Officer (8)

0001193125-26-276096 · SEC table 652 row 16 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Paul Berns · Paul Berns — Beneficial shares · 53,483

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Paul Berns (9)

0001193125-26-276096 · SEC table 652 row 18 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

David Meeker, M.D. · David Meeker, M.D. — Beneficial shares · 37,358

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: David Meeker, M.D. (10)

0001193125-26-276096 · SEC table 652 row 19 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Douglas Giordano · Douglas Giordano — Beneficial shares · 53,483

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Douglas Giordano (11)

0001193125-26-276096 · SEC table 652 row 20 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Kim Popovits · Kim Popovits — Beneficial shares · 37,358

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: Kim Popovits (12)

0001193125-26-276096 · SEC table 652 row 21 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

Entities affiliated with ARCH · Entities affiliated with ARCH — Beneficial ownership · 22.4%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with ARCH (1)

0001193125-26-276096 · SEC table 652 row 7 columns 8; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:6 ↗

Entities affiliated with ARCH · Entities affiliated with ARCH — Beneficial ownership · 16.5%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with ARCH (1)

0001193125-26-276096 · SEC table 652 row 7 columns 12; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:9 ↗

Entities affiliated with HRTG Partners · Entities affiliated with HRTG Partners — Beneficial ownership · 22.4%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with HRTG Partners (2)

0001193125-26-276096 · SEC table 652 row 8 columns 8; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:6 ↗

Entities affiliated with HRTG Partners · Entities affiliated with HRTG Partners — Beneficial ownership · 16.6%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with HRTG Partners (2)

0001193125-26-276096 · SEC table 652 row 8 columns 12; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:9 ↗

Entities affiliated with Perceptive · Entities affiliated with Perceptive — Beneficial ownership · 12.7%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with Perceptive (3)

0001193125-26-276096 · SEC table 652 row 9 columns 8; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:6 ↗

Entities affiliated with Perceptive · Entities affiliated with Perceptive — Beneficial ownership · 9.3%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with Perceptive (3)

0001193125-26-276096 · SEC table 652 row 9 columns 12; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:9 ↗

Entities affiliated with Fidelity · Entities affiliated with Fidelity — Beneficial ownership · 6.9%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with Fidelity (4)

0001193125-26-276096 · SEC table 652 row 10 columns 8; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:6 ↗

Entities affiliated with Fidelity · Entities affiliated with Fidelity — Beneficial ownership · 5.1%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with Fidelity (4)

0001193125-26-276096 · SEC table 652 row 10 columns 12; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:9 ↗

Tassos Gianakakos, Chief Executive Officer, Director, and Chair · Tassos Gianakakos, Chief Executive Officer, Director, and Chair — Beneficial ownership · 15.2%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Tassos Gianakakos, Chief Executive Officer, Director, and Chair (5)

0001193125-26-276096 · SEC table 652 row 13 columns 8; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:6 ↗

Tassos Gianakakos, Chief Executive Officer, Director, and Chair · Tassos Gianakakos, Chief Executive Officer, Director, and Chair — Beneficial ownership · 11.2%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Tassos Gianakakos, Chief Executive Officer, Director, and Chair (5)

0001193125-26-276096 · SEC table 652 row 13 columns 12; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:9 ↗

Jay Edelberg, M.D., Ph.D., Chief Medical Officer · Jay Edelberg, M.D., Ph.D., Chief Medical Officer — Beneficial ownership · 7.1%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Jay Edelberg, M.D., Ph.D., Chief Medical Officer (6)

0001193125-26-276096 · SEC table 652 row 14 columns 8; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:6 ↗

Jay Edelberg, M.D., Ph.D., Chief Medical Officer · Jay Edelberg, M.D., Ph.D., Chief Medical Officer — Beneficial ownership · 5.2%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Jay Edelberg, M.D., Ph.D., Chief Medical Officer (6)

0001193125-26-276096 · SEC table 652 row 14 columns 12; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:9 ↗

All executive officers and directors as a group (10 persons) · All executive officers and directors as a group (10 persons) — Beneficial shares · 14,803,609

Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition

Raw source column: Number of sharesbeneficially owned; source holder: All executive officers and directors as a group (10 persons)

0001193125-26-276096 · SEC table 652 row 23 columns 4; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 4:3 ↗

All executive officers and directors as a group (10 persons) · All executive officers and directors as a group (10 persons) — Beneficial ownership · 22.6%

Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: All executive officers and directors as a group (10 persons)

0001193125-26-276096 · SEC table 652 row 23 columns 8; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:6 ↗

All executive officers and directors as a group (10 persons) · All executive officers and directors as a group (10 persons) — Beneficial ownership · 16.6%

Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition

Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: All executive officers and directors as a group (10 persons)

0001193125-26-276096 · SEC table 652 row 23 columns 12; source 1873964:1889013; SHA256 22cafbe799e90b8f8982231c0d4803f2b756d48bb5d37274ba7cd3ebba1fb822; ownership header cells 3:6,4:9 ↗

voting common stock · voting common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; voting common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable

Except as otherwise expressly provided in our amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our voting common stock are entitled to one vote per share of voting common stock, and holders of our non-voting common stock are not entitled to any votes per share of non-voting common stock, including for the election of directors. In particular, under Section 242(b)(2) of the DGCL, holders of non-voting common stock are entitled to vote separately as a class on amendments to a certificate of incorporation that adversely affects the powers, preferences or special rights of that class. Holders of our voting common stock have no conversion rights, while holders of our non-voting common stock shall have the right to convert each share of our non-voting common stock into one share of voting common stock at such holder’s election, provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 9.99% of our common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in our amended and restated certificate of incorporation. However, this ownership limitation may be increased or decreased to any other percentage (not to exceed 19.99%) designated by such holder of non-voting common stock upon 61 days’ notice to us. There are no mandatory conversion terms associated with the non-voting common stock. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock and non-voting common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for Source context: The following description of our capital stock and certain provisions of our third amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the third amended and restated certificate of incorporation, which will become effective upon the completion of this offering, and the amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents have been filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion of this offering.

0001193125-26-276096 · SEC ownership excerpt; source 1908009:1909944; SHA256 de8b91b52ec0cfe0ae002250b8a992aed0e37ee76b09210a38bc218cffd217c3; context source 1905404:1906274; SHA256 0f6ec7eda1cef03987ea83e0640b003da38901a81f7375a48dcff6535969beb7 ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

Share supply

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
WeAfter date of this prospectus · Source conditions apply180 days
our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which theyAfter date of this prospectus · Source conditions apply180 days
Source and calculation
We

We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus (such period, the “restricted period”), other than the shares of our common stock to be sold in this offering.

SEC lock-up paragraph; source 2000552:2001889; SHA256 16054ac746afd4d76ce8469ab544ddfb3934a373058b267aaa0a1e8e84bd8950 ↗
our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they

All shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities Act”), unless held by our “affiliates” as defined in Rule 144 under the Securities Act. The resale of the remaining 64,301,057 shares, or 72.0% of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they have agreed or will agree, subject to specific exceptions described in the section of this prospectus titled “Underwriting,” not to sell any of our stock for 180 days following the date of this prospectus. We refer to such period as the lock-up period. We and certain of the underwriters may release certain stockholders from the market standoff agreements or lock-up agreements prior to the end of the lock-up period. Subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled “Shares Eligible for Future Sale” included elsewhere in this prospectus.

SEC lock-up paragraph; source 738245:740515; SHA256 dd1b4e091f6f3f2e67f8eb1408e38ccca4066021e97f18da36061b41c5c9301c ↗

Source lock-up conditions

Literal day restriction; source duration bound ≥; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or exchangeable for our capital stock, representing 64,301,057 shares of our common stock,≥180 days
Source and calculation
We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or exchangeable for our capital stock, representing 64,301,057 shares of our common stock,

We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or exchangeable for our capital stock, representing 64,301,057 shares of our common stock, have entered into lock-up agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from selling any of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180 days from the date of this prospectus without the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, subject to certain exceptions. See the section titled “Underwriting” appearing elsewhere in this prospectus for more information.

SEC lock-up paragraph; source 1953847:1954834; SHA256 6ef4b651bbc2bb348d17cab6a7411e3bc0e257a935c667381fca5173ee0efd3e ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

date of this prospectus

  1. WeWe have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus (such period, the “restricted period”), other than the shares of our common stock to be sold in this offering.
  2. our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which theyAll shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities Act”), unless held by our “affiliates” as defined in Rule 144 under the Securities Act. The resale of the remaining 64,301,057 shares, or 72.0% of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they have agreed or will agree, subject to specific exceptions described in the section of this prospectus titled “Underwriting,” not to sell any of our stock for 180 days following the date of this prospectus. We refer to such period as the lock-up period. We and certain of the underwriters may release certain stockholders from the market standoff agreements or lock-up agreements prior to the end of the lock-up period. Subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled “Shares Eligible for Future Sale” included elsewhere in this prospectus.
Holder / event
Holder / eventTerm / dateConditions
We180 daysWe have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus (such period, the “restricted period”), other than the shares of our common stock to be sold in this offering.
our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they180 daysAll shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities Act”), unless held by our “affiliates” as defined in Rule 144 under the Securities Act. The resale of the remaining 64,301,057 shares, or 72.0% of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they have agreed or will agree, subject to specific exceptions described in the section of this prospectus titled “Underwriting,” not to sell any of our stock for 180 days following the date of this prospectus. We refer to such period as the lock-up period. We and certain of the underwriters may release certain stockholders from the market standoff agreements or lock-up agreements prior to the end of the lock-up period. Subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled “Shares Eligible for Future Sale” included elsewhere in this prospectus.
Basis and evidence
We

We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus (such period, the “restricted period”), other than the shares of our common stock to be sold in this offering.

SEC lock-up paragraph; source 2000552:2001889; SHA256 16054ac746afd4d76ce8469ab544ddfb3934a373058b267aaa0a1e8e84bd8950 ↗
our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they

All shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities Act”), unless held by our “affiliates” as defined in Rule 144 under the Securities Act. The resale of the remaining 64,301,057 shares, or 72.0% of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they have agreed or will agree, subject to specific exceptions described in the section of this prospectus titled “Underwriting,” not to sell any of our stock for 180 days following the date of this prospectus. We refer to such period as the lock-up period. We and certain of the underwriters may release certain stockholders from the market standoff agreements or lock-up agreements prior to the end of the lock-up period. Subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled “Shares Eligible for Future Sale” included elsewhere in this prospectus.

SEC lock-up paragraph; source 738245:740515; SHA256 dd1b4e091f6f3f2e67f8eb1408e38ccca4066021e97f18da36061b41c5c9301c ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Net income / (loss)

$ · Annual values as reported · Consolidated
FY2024($88,658)
FY2025($191,941)

Operating cash flow

$ · Annual values as reported · Consolidated
FY2024($18,825)
FY2025($151,056)
Financial quality
CalculationFY2024FY2025
Net income / (loss)Consolidated($88,658)($191,941)
Operating cash flowConsolidated($18,825)($151,056)
Financial quality
CalculationReported value
Cash and cash equivalents2025-12-31 · Consolidated$108,989
Cash and cash equivalents2024-12-31 · Consolidated$49,402
Current assets2025-12-31 · Consolidated$345,353
Current assets2024-12-31 · Consolidated$50,318
Total assets2025-12-31 · Consolidated$390,942
Total assets2024-12-31 · Consolidated$63,526
Current liabilities2025-12-31 · Consolidated$37,536
Current liabilities2024-12-31 · Consolidated$8,285
Total liabilities2025-12-31 · Consolidated$55,127
Total liabilities2024-12-31 · Consolidated$26,698
Total equity / (deficit)2025-12-31 · Consolidated($250,335)
Total equity / (deficit)2024-12-31 · Consolidated($83,194)
General and administrative expensesFY2025 · Consolidated$48,750
General and administrative expensesFY2024 · Consolidated$12,362
Cash and cash equivalents2026-03-31 · Consolidated · Unaudited$81,548
Cash and cash equivalents2025-12-31 · Consolidated · Unaudited$108,989
Current assets2026-03-31 · Consolidated · Unaudited$298,134
Current assets2025-12-31 · Consolidated · Unaudited$345,353
Total assets2026-03-31 · Consolidated · Unaudited$348,190
Total assets2025-12-31 · Consolidated · Unaudited$390,942
Current liabilities2026-03-31 · Consolidated · Unaudited$31,665
Current liabilities2025-12-31 · Consolidated · Unaudited$37,536
Total liabilities2026-03-31 · Consolidated · Unaudited$51,270
Total liabilities2025-12-31 · Consolidated · Unaudited$55,127
Total equity / (deficit)2026-03-31 · Consolidated · Unaudited($300,626)
Total equity / (deficit)2025-12-31 · Consolidated · Unaudited($250,335)
General and administrative expenses3M ended 2026-03-31 · Consolidated · Unaudited$13,643
General and administrative expenses3M ended 2025-03-31 · Consolidated · Unaudited$7,304
Net income / (loss)3M ended 2026-03-31 · Consolidated · Unaudited($56,071)
Net income / (loss)3M ended 2025-03-31 · Consolidated · Unaudited($18,019)
Operating cash flow3M ended 2026-03-31 · Consolidated · Unaudited($56,776)
Operating cash flow3M ended 2025-03-31 · Consolidated · Unaudited($21,400)
Basis and evidence
Cash and cash equivalents
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Cash and cash equivalents
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current assets
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total assets
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current liabilities
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total liabilities
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total stockholders’ deficit
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
General and administrative
FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
General and administrative
FY2024; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net loss
FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net loss
FY2024; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net cash used in operating activities
FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities
FY2024; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Cash and cash equivalents
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Cash and cash equivalents
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current assets
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total assets
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current liabilities
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total liabilities
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total stockholders’ deficit
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
General and administrative
3M ended 2026-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
General and administrative
3M ended 2025-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Net loss
3M ended 2026-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Net loss
3M ended 2025-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Net cash used in operating activities
3M ended 2026-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Net cash used in operating activities
3M ended 2025-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Financial quality and runway
Financial review

Financial quality and runway

Latest March 2026 data show $287.1 million cash/investments but a $56.1 million quarterly loss and explicit pre-IPO going-concern doubt.

Cash and cash equivalents$108,989
Cash and cash equivalents$49,402
Total current assets$345,353
EvidenceFinancial review 1

First-quarter 2026 R&D was $45.067 million and total operating expenses $58.710 million, versus $18.774 million and $26.078 million a year earlier.

Source · Summary Consolidated Financial Data, page 10, lines 705-790.Open 424B4 ↗
EvidenceFinancial review 2

First-quarter 2026 net loss was $56.071 million versus $18.019 million in first-quarter 2025; full-year 2025 loss was $191.941 million.

Source · Summary Consolidated Financial Data, page 10, lines 760-840.Open 424B4 ↗
EvidenceFinancial review 3

At March 31, 2026, cash was $81.548 million, short-term investments $205.560 million, total assets $348.190 million and liabilities $51.270 million.

Source · Summary Consolidated Financial Data — Balance Sheet, page 11, lines 850-930.Open 424B4 ↗
EvidenceFinancial review 4

Management concluded pre-IPO resources were insufficient for at least 12 months, but estimates IPO proceeds and existing funds support operations into 2028.

Source · MD&A — Liquidity, pages 118-119, lines 5895-5910; Use of Proceeds, page 110.Open 424B4 ↗
LATEST COMPARISON

Baseline filing — comparison pending

No source-comparable material changes identified in this report.

Open 424B4 ↗

No source-comparable material changes identified in this report.

IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.

Loading filing history…

Document424B40001193125-26-276096
Filed2026-06-18SEC EDGAR
Research updated2026-09-16Analysed
Source-bound table inputs74SEC EDGAR
Open filing ↗